Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KIT V560D |
| Therapy | Imatinib |
| Indication/Tumor Type | mucosal melanoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KIT V560D | mucosal melanoma | predicted - sensitive | Imatinib | Case Reports/Case Series | Actionable | In a Phase II trial, Gleevec (imatinib) treatment resulted in a best overall response rate of 53.8% (7/13, all partial responses) in patients with mucosal, acral, or chronically sun-damaged skin melanoma harboring KIT activating mutations in exons 11 (n=9), 13 (n=3), and 17 (n=1), including a partial response with a progression-free survival of 4.5 months and an overall survival of 9.1 months in a patient with mucosal melanoma harboring KIT V560D (PMID: 23775962; NCT00424515). | 23775962 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (23775962) | Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. | Full reference... |